Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06607185 | A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | PHASE1 | ACTIVE NOT_RECRUITING | 750 | — | — | Oct 21, 2024 | Jan 1, 2030 | May 26, 2026 | 47 | United States, Belgium +6 |
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
| Arm | Type | Description |
|---|---|---|
| LY4066434 Monotherapy Dose Escalation | EXPERIMENTAL | Escalating doses of LY4066434 administered orally. |
| LY4066434 Dose Optimization | EXPERIMENTAL | LY4066434 administered orally either alone or with another investigational agent. |
| Name | Type | Description |
|---|---|---|
| LY4066434. | DRUG | Administered orally. |
| Cetuximab | DRUG | Administered intravenously. |
| Nab paclitaxel | DRUG | Administered intravenously. |
| Gemcitabine | DRUG | Administered intravenously. |
| Oxaliplatin | DRUG | Administered intravenously. |
| Leucovorin | DRUG | Administered intravenously. |
| Irinotecan | DRUG | Administered intravenously. |
| 5Fluorouracil | DRUG | Administered intravenously. |
| Carboplatin | DRUG | Administered intravenously. |
| Cisplatin | DRUG | Administered intravenously. |
| Pemetrexed | DRUG | Administered intravenously. |
| Pembrolizumab | DRUG | Administered intravenously. |
Inclusion Criteria: * Have evidence of KRAS G12C, G12D, G12V, G12A, G12S, or G13D mutation in tumor tissue or circulating tumor DNA * Histological or cytologically proven diagnosis of a locally advanced, unresectable, and/or metastatic solid tumor cancer * Have measurable disease per RECIST 1.1 * H...